Substance / Medication

Selpercatinib

Overview

Active Ingredient
selpercatinib
RxNorm CUI
2370147
Labeler: Eli Lilly and CompanyUpdated: 2025-11-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
CNS Protective Effect of Selpercatinib in First-LineFusion-Positive Advanced Non-Small Cell Lung Cancer.
Pérol Maurice, Solomon Benjamin J, Goto Koichi et al. · J Clin Oncol · 2024
PMID: 38828957RCTFull text (PMC)
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.
Mihashi Yasuhiro, Komuta Kiyohide, Tsukaguchi Akihiro et al. · Invest New Drugs · 2025
PMID: 41272381Observational
Matching-adjusted indirect comparison of selpercatinib and pralsetinib infusion-positive non-small cell lung cancer.
Hochmair Maximilian, Kiiskinen Urpo, D'yachkova Yulia et al. · Future Oncol · 2025
PMID: 40458063ObservationalFull text (PMC)
Erectile Dysfunction in Patients Treated with Selpercatinib for-Altered Thyroid Cancer.
Matrone Antonio, Kroiss Matthias, Gild Matti L et al. · Thyroid · 2024
PMID: 38984927Observational
Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.
Betsema Lyan, Jacobs Bart A W, Huitema Alwin D R et al. · Cancer Chemother Pharmacol · 2026
PMID: 41484433Case Report
A Case of Stevens-Johnson Syndrome Induced by Selpercatinib.
Tone Yuki, Matsui Mami, Park Aeri et al. · J Dermatol · 2025
PMID: 40237476Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Selpercatinib (substance)
SNOMED CT
876841001
UMLS CUI
C5235396
RxNorm CUI
2370147
Labeler
Eli Lilly and Company

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.